What Xatral SR Treats: Main Uses and Benefits

Xatral SR is commonly used to address the signs and symptoms associated with an enlarged prostate, a condition medically known as Benign Prostatic Hyperplasia (BPH). This medicine is indicated for managing these symptomatic manifestations. It helps address symptom clusters that may become intense or disruptive, falling under the umbrella of lower urinary tract symptoms (LUTS).

This medication is generally applied across domains where additional symptomatic support is needed, particularly during phases when LUTS become more noticeable. It is used in areas where short-term symptom management is appropriate and contributes to easing the overall symptom load.

Key symptomatic areas include hesitancy, a weak urinary stream, incomplete bladder emptying, and the increased frequency and urgency of urination. By helping to manage these issues, Xatral SR assists with maintaining functional stability when symptoms interfere with routine activities.

Quick Fact: Relief for Lower Urinary Tract Symptoms (LUTS)

Xatral SR (alfuzosin) is an alpha-blocker primarily used to treat symptoms of Benign Prostatic Hyperplasia (BPH), or enlarged prostate, in adult men. It is not indicated for use in women or in the pediatric population (those under 16 years of age).

Contraindications (Who Should Not Use Xatral SR)

This medication should generally not be used by individuals with:

• Known allergy or hypersensitivity to alfuzosin or any other component of the tablet.
• Moderate to severe liver impairment (hepatic insufficiency).
• A history of orthostatic hypotension (a significant drop in blood pressure upon standing, leading to dizziness or fainting).
• Severe kidney impairment (creatinine clearance <30 ml/min) in some formulations.
• Concurrent use of other alpha-blockers (such as prazosin, tamsulosin, or doxazosin).
• Concurrent use of potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, or ritonavir), as these can dangerously increase alfuzosin levels.

Precautions (Use with Caution)

Patients with certain other health conditions require careful medical assessment before starting treatment, including those with pre-existing heart conditions (e.g., angina, severe heart failure, or prolonged QT interval) or a history of marked hypotensive response to other alpha-blockers. Consultation is vital to ensure safe use, especially for elderly patients who may be more susceptible to the hypotensive effects.

Interactions with other medicines and products

Official regulatory information for Xatral SR (Alfuzosin hydrochloride) establishes two main interaction risks: increased drug exposure and enhanced blood pressure lowering (hypotension).

Contraindicated Combinations

Co-administration is strictly contraindicated with two classes of products:

• Other Alpha-1 Adrenergic Antagonists (e.g., doxazosin, tamsulosin), due to the expected, significant risk of additive blood pressure lowering and postural hypotension.
• Potent CYP3A4 Inhibitors (e.g., ketoconazole, ritonavir), because they block the metabolism of Alfuzosin, resulting in a clinically significant increase in its blood levels (Cmax and AUC).

Other Documented Interactions and Restrictions

Alpha-1 Adrenergic Receptor Antagonism

Alfuzosin is an alpha-1 mathbfalpha1 adrenoceptor antagonist that acts within the sympathetic nervous system pathways to modulate smooth muscle tone. This selective binding process inhibits the activation of these receptors by natural signaling molecules like norepinephrine.

Smooth Muscle Tone Modulation

By inhibiting alpha1-adrenoceptors on smooth muscle cells, the compound engages mechanisms that modulate contractile force. The resulting physiological effect is a reduction in smooth muscle tone in the bladder neck, prostate, and prostatic urethra.

Altered Pressure Gradient

This reduction in smooth muscle tone leads to a cascade effect: it lowers the effective resistance at the bladder outlet. This contributes to a shift in basal tone within the affected pathway, resulting in an altered pressure gradient across the prostatic urethra.

How to Use Xatral SR: Official Administration Guidelines

Xatral SR (10 mg prolonged-release tablets) must be used strictly according to the established administration rules. This section outlines the standard protocols, encompassing dosing, frequency, and critical handling instructions.

Dosing and Administration Schedule

Essential Administration Rules

• Tablet Integrity: The prolonged-release tablet must be swallowed whole with a sufficient amount of liquid. It is a critical restriction that the tablet must not be crushed, chewed, divided, or otherwise altered to prevent improper release of the active substance, Alfuzosin hydrochloride.
• Missed Dose: If a dose is missed, the patient should skip the missed dose and take the next dose at the regularly scheduled time after the next meal. A double dose should never be taken to compensate for a missed dose.
• Age-Specific Rules: For older adults (patients 65 years and older), the standard 10 mg once-daily dose does not typically require adjustment. The medication is not indicated for use in the pediatric population.

Research evidence / Overview of studies for Xatral SR

Evidence for Use in Lower Urinary Tract Symptoms (LUTS) related to BPH

The primary research for Xatral SR (Alfuzosin Extended-Release) has been short-term, placebo-controlled randomized clinical trials (RCTs). These studies were designed to evaluate measurements related to the substance over periods typically lasting 4 to 12 weeks. Researchers used these trials to examine patient experiences related to research endpoints related to symptom severity and measurements reflecting quality of life. This included monitoring changes in the International Prostate Symptom Score (IPSS), a tool used to track symptom intensity and perceived discomfort.

The research also explored functional changes in the lower urinary system, monitoring Peak Urinary Flow Rate and Post-Void Residual (PVR) urine volume in adult men with LUTS that suggested Benign Prostatic Hyperplasia (BPH). These research efforts describe findings reported in the study documents regarding subjective symptom scores and objective measurements of flow. Subsequent systematic reviews and meta-analyses have synthesized the findings from these initial RCTs, reporting variations in the measurement of functional flow rate across the trials.

Evidence Regarding BPH Progression and Long-Term Outcomes

Studies have explored research questions related to the overall clinical course of BPH, known as BPH progression. This area was evaluated primarily through one large, long-term Randomized Controlled Trial that monitored responses over a period of up to two years. The study was designed to monitor the incidence of major BPH-related events, such as the incidence of Acute Urinary Retention (AUR) requiring medical help or the need for BPH-related surgery.

In this long-term study, when the researchers specifically analyzed the AUR incidence alone, no discernible difference in incidence was observed between the active substance and the placebo. However, the same study described patterns in the tracked incidence rates when analyzing a composite endpoint of overall clinical progression. The research for progression tracking is limited as it rests largely on the findings of a single major study.

Common questions about Xatral SR (FAQ)

Q: What is the active ingredient in Xatral SR and what is it used for?

According to the official product information, the active ingredient in Xatral SR is alfuzosin hydrochloride. This medicine is indicated for the treatment of moderate to severe symptoms associated with benign prostatic hyperplasia (BPH) in men. BPH is a non-cancerous enlargement of the prostate gland that can cause urinary problems.

Q: Can I take Xatral SR if I have severe kidney problems?

Regulatory documents state that Xatral SR is generally contraindicated in patients who have severe kidney insufficiency. Severe kidney problems are defined in official information as having a creatinine clearance of less than 30 ml/min. For individuals with severe kidney issues, official guidance states that use of this medicine is contraindicated.

Q: Is Xatral SR suitable for women?

Official information indicates that Xatral SR is not intended for use by women. This medicine is specifically indicated and studied for the treatment of benign prostatic hyperplasia (BPH), which is a condition that affects men.

Q: Will this drug cure my enlarged prostate forever?

Studies and official information indicate that Xatral SR works by managing the symptoms of BPH, such as difficulty or frequent urination. It belongs to a class of drugs that help relax the muscle in the prostate and bladder neck. However, the medicine does not provide a permanent cure for the underlying enlarged prostate condition itself.

Q: Is it safe to drive after taking Xatral SR?

According to the official product information, caution is advised regarding driving or operating machinery. This is because Xatral SR may cause side effects such as dizziness, vertigo, or fatigue (asthenia). Official information advises that extra caution may be necessary when these effects are more likely, such as during the initial phase of treatment.

Official Storage and Disposal Requirements

The storage and disposal of Xatral SR (alfuzosin hydrochloride) tablets must strictly adhere to regulatory labeling to maintain safety and efficacy.

These constraints define how the product must be protected from environmental factors and handled post-use, in alignment with public safety standards and local regulations.